Analysts at Bank of America started coverage on shares of Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) in a research report issued to clients and investors on Monday, Marketbeat Ratings reports. The firm set an “underperform” rating and a $150.00 price target on the biopharmaceutical company’s stock. Bank of America‘s target price would suggest a […]
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) has received an average rating of “Moderate Buy” from the ten research firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 12-month price […]
StockNews.com upgraded shares of Madrigal Pharmaceuticals (NASDAQ:MDGL – Free Report) to a sell rating in a research report report published on Thursday. Several other brokerages also recently commented on MDGL. UBS Group raised their target price on Madrigal Pharmaceuticals from $337.00 to $410.00 and gave the company a buy rating in a research note on […]
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) has earned an average rating of “Moderate Buy” from the seven research firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year price objective […]
Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) have been given an average recommendation of “Moderate Buy” by the seven research firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The […]